• By ICR Secretariat
  • Posted Monday, August 1, 2022

FDA puts the microscope on 2 more cancer approvals without voluntary withdrawals


The FDA’s oncology department has lately been tightening its act around accelerated approvals and stressing the importance of patient survival data. Several companies immediately fell in line, withdrawing problematic indications when the agency mounted its pressure. But some companies have decided to put up a fight.